CAR T Therapy as a New Option in Non-Hodgkin Lymphoma: Michael R. Bishop, MD

Video

The hematological oncologist from University of Chicago Medicine discussed chimeric antigen receptor T cells therapy in non-Hodgkin lymphoma.

This content originally appeared on our sister site, Targeted Oncology.

OncLive spoke with Michael R. Bishop, MD, hematological oncologist, professor of Medicine, and director, Hematopoietic Stem Cell Transplant Program, University of Chicago Medicine, to learn more about chimeric antigen receptor (CAR) T cells therapy in non-Hodgkin lymphoma.

Bishop discussed how CAR T cells provide another option for patients with mantel cell lymphoma and yield a higher stable remission rate in this indication compared to diffuse large B-cell lymphoma. Sustained complete remissions without any further therapy have also been observed, but questions remain around sustainability and long-term data.

Results are still pending in indolent lymphomas such as follicular lymphoma. However, according to Bishop, initial results are encouraging. Trial results are expected in the end of 2021. In terms of multiple myeloma, duration of responses have not been as high as in lymphomas, but are improving overtime.

0:08 | It provides an additional option. There's lots of options for mantle cell lymphoma, but the CAR T-cell results had a higher response rate. And a significant proportion entering into stable remission are higher than what we've seen in diffuse large B-cell lymphoma. The long-term data is yet to be determined, and rather relative to the impact on their natural history, but there are sustained complete remissions without any further therapy and we just got to see how long those are going to last.

0:46 | And we are waiting for additional results in other forms of non-Hodgkin lymphoma, particularly in indolent lymphomas, such as follicular lymphoma, the initial results are extremely encouraging. We now have some additional info when you consider chronic lymphocytic leukemia and small lymphocytic lymphoma, we do consider that to be initially encouraging results. So, we're going have these trials available to us, the results of that, within this year. And then finally, coming back to multiple myeloma, as I mentioned, we're going to have our first approved product, what we expect to be commercially available in March of this year, and a number of trials that are highly exciting variations on the approaches in terms of what targets and dual targeting and, and different receptors. And these results have been highly exciting in terms of very, very high response rates. I think the disappointing aspect of multiple myeloma, we aren't seeing the sustained remissions that we're observing in leukemias and lymphomas, but we are seeing improvement across protocols over time. So, I think it's an exciting time for patients to have these various options.

Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Related Content
© 2024 MJH Life Sciences

All rights reserved.